

FDA Guidance May Move Goalposts For Form 483 Responses

By **Sonia Nath, Laura Akowuah and Auguste Humphries** (April 8, 2026)

The [U.S. Food and Drug Administration](#) has issued new draft guidance giving drug manufacturers — for the first time — formal guidance on how the agency expects firms to respond to a Form 483, following an inspection.

The guidance is broad in scope and applies to both foreign and domestic facilities that manufacture human or animal drugs regulated by the Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, or Center for Veterinary Medicine, extending to combination-product manufacturers when CDER or CBER is the lead center.

Until now, companies have largely relied on experience and institutional knowledge to determine what a good response looks like. This draft guidance puts structure around the process, signaling that the FDA now expects Form 483 responses to follow a more consistent structure, and be clearly tied to the strength and reliability of a facility's broader quality system.

The FDA also explicitly asks manufacturers to identify the response preparer and, if the preparer is not the company itself, to provide a letter of authorization from the consultant or outside counsel who prepared the response on the manufacturer's behalf.


Moreover, the FDA is specific in its requests for large-scale compliance efforts, such as reports covering global pharmacovigilance investigations. In this way, the new guidance articulates what FDA insiders have often advised: The FDA wants to see that a company has not only addressed, or is actively addressing, the observations in a Form 483, but is also fully assessing and correcting any underlying systemic issues.

Recommended Practices

The draft guidance highlights several elements that the FDA views as important for a robust response. Multiple of these elements relate to format or other logistical requirements — a



Sonia Nath



Laura Akowuah



Auguste Humphries

table of contents, a copy of the Form 483, the identity of the response preparer and letters of authorization if the company retained a consultant or outside counsel.

More substantively, the FDA recommends an executive summary of all remediation activities, followed by a more detailed description of each observation and associated remediation plans, including risk assessments of the observations, detailed investigation reports and signed attachments to support the company's response.

Disagreements

The FDA recommends that companies seek clarification and address disagreements related to scientific or technical issues during an inspection with FDA investigators. If a significant disagreement is not resolved before issuance of the Form 483, companies should communicate these concerns in their Form 483 response.

Companies will want to describe the contested facts and provide scientific data and supporting information to allow the FDA to better evaluate the concern. Moreover, companies should reference applicable laws, regulations and guidance that support their position.

Preliminary Results and Interim Reporting

The FDA recommends that, if there are remediation activities that are not complete at the time a company submits its response, which is often the case, the company should submit preliminary results with a timeline for completion.

Companies should also highlight interim measures put in place until the corrective actions and preventive actions, or CAPAs, are complete. The FDA expects CAPA plans to be measurable and verifiable, and companies can expect such plans to be evaluated by the FDA in a future inspection to ensure the planned actions were effectively implemented.

Importance of Timing

The 15-business-day time frame for a Form 483 response is critical. Although a company is not required to provide a response within this time frame, timely submission improves a company's likelihood of avoiding a compliance or enforcement action. That said, some corrective actions, particularly those of a holistic nature, the FDA expects, cannot be accomplished in a 15-day time frame.

Moreover, the FDA states in the draft guidance that it will not typically delay a regulatory action, such as issuing a warning letter, particularly if the FDA observed significant deficiencies concerning product quality or patient safety during the inspection.

This leaves companies in the hard position of promising comprehensive corrective actions on a broader scale and wanting to submit complete responses within the 15-day time frame that reflect the actions the company has taken in that time period. In this way, the guidance may not actually achieve the FDA's goals, leaving manufacturers to determine the best strategy for the Form 483 response in light of their specific timelines for corrective actions.

See the Big Picture

While the draft guidance clarifies what the FDA expects to see in an individual response, it also makes clear that the agency is looking for companies to conduct systemic investigations and assess observations in the context of their overall quality system.

Specifically, the FDA encourages companies to explain "conditions or systemic issues that led to the observations," and to include information about "the scope of the issue, effect on other drugs, and whether the observation is an isolated incident or is systemic in nature."

Put simply, the FDA wants to understand whether a finding reflects a one-off problem or evidence of a broader breakdown. The guidance also notes that firm management plays an important role in ensuring the quality system can support this kind of evaluation, and in maintaining the overall effectiveness of the system.

Manufacturers should be prepared for the FDA to continue to take a broad view of their operations as it evaluates the response. The FDA will consider not only the observation itself, but also what the company's assessment and supporting information reveal about the strength and effectiveness of its quality system.

Practical Concerns

The guidance raises some practical concerns that may warrant submission of comments for the agency's consideration. For example, as discussed above, the tension between the 15-business-day response window and the breadth of information the FDA expects in the initial response, coupled with the agency's position that it will not ordinarily delay

regulatory action to review late-submitted responses, could disadvantage many small and midsize companies.

Although the guidance encourages interim reporting, it does not expressly commit the FDA to considering such submissions in its enforcement decision-making. This dynamic could encourage companies to rush comprehensive investigations to avoid having their assessments and corrective actions disregarded.

The bottom line is that companies should continue to prioritize submitting as comprehensive a response as possible within the 15-business-day window. A timely, well-organized submission that acknowledges ongoing remediation efforts can demonstrate good faith and may position a company more favorably if the FDA initiates further enforcement action.

This is particularly important in the context of more serious enforcement tools, such as injunctions. To obtain injunctive relief, the FDA must show, among other things, a likelihood of recurring violations, and that the company is unwilling or unable to comply with the law.

A company's documented efforts to investigate and remediate Form 483 observations — including interim reports and CAPA implementation timelines — may be directly relevant to that analysis and could undermine the FDA's ability to satisfy this standard.

In addition, the guidance appears to take an expansive view of quality investigation requirements. It recommends that companies prepare an investigation plan that includes a detailed protocol and methodology, a scientifically justified and risk-based scope, and justification for excluding any part of an establishment's operations from the investigation.

These recommendations — together with the guidance's recommendation that a comprehensive investigation plan be prepared to address the FDA's Form 483 observations by including identification of any related trends, linking any connected Form 483 observations, assessing risks and analyzing root cause — appear to go beyond what is currently required under existing regulations.

Thus, this particular area seems to merit industry comments, as the guidance's detailed recommendations concerning the form and substance of the Form 483 response may set a higher bar than current regulations warrant.

Looking Ahead

In short, while the draft guidance provides a helpful framework,[1] it leaves important questions unanswered, including the role of interim submissions and how the FDA will weigh ongoing remediation efforts in its enforcement decision-making.

[Sonia Nath](#) is a partner and chair of the global life sciences and healthcare regulatory practice group at [Cooley LLP](#).

[Laura Akowuah](#) is special counsel at the firm.

[Auguste Humphries](#) is an associate at the firm.

The opinions expressed are those of the author(s) and do not necessarily reflect the views of their employer, its clients, or Portfolio Media Inc., or any of its or their respective affiliates. This article is for general information purposes and is not intended to be and should not be taken as legal advice.

[1] This draft guidance does not apply to medical devices and, thus, device companies should continue to follow 21 CFR Part 820 and related guidance concerning device inspections. However, some key points from the draft guidance, including the importance of submitting a 483 response within 15 business days and developing comprehensive, risk-based CAPA plans with root-cause analysis, provide useful guidance for device firms as well.